ArticleArchives of microbiology2025
Design and development of a novel multi-epitope DNA vaccine candidate against infectious bronchitis virus: an immunoinformatic approach.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-Epitope DNA-Based Feline Immunodeficiency Virus Vaccine Construct Designed by Immunoinformatic and Machine Learning Tools as a Surrogate Model for HIV Vaccine Development.Pathogens (Basel, Switzerland) · 2026Article
- Immunoinformatics-driven design of a conserved RNA-dependent RNA polymerase-based multi-epitope vaccine against avian infectious bronchitis virus.Veterinary world · 2026Article
- Emergence of novel QX-type IBV in China: molecular insights into unique S protein cleavage sites, antigenic drift, and enhanced pathogenicity (2025).BMC veterinary research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Avian infectious bronchitis (IB) is one of the major respiratory diseases in poultry. At present, attenuated vaccines are the main commercial vaccines, but they have many defects. We aimed to construct a novel multi-epitope DNA vaccine based on avian infectious bronchitis virus (IBV) S1 and N proteins for the prevention of IBV infection. We screened the dominant B and T cell epitopes of target proteins utilizing epitope prediction tools. A new high-immunogenicity epitope peptide segment named QSN was designed and screened by linking peptide. The physicochemical properties of QSN were analyzed by bioinformatics. The recombinant plasmid pEGFP-QSN was obtained by inserting the synthesized QSN gene into the eukaryotic expression vector pEGFP-N1. On the 7th day of age, chicks were immunized by intramuscular injection of the plasmid, and serum specific antibody IgG, cytokines IFN-γ and IL-2, and T lymphocyte subsets were detected after booster immunization. Bioinformatics analysis showed that QSN had high hydrophilicity without transmembrane region and stable structure after binding to receptor. The recombinant eukaryotic vector was successfully constructed. Two weeks after booster immunization, compared with NS group and pEGFP-N1 group, serum IgG level, concentrations of cytokines IFN-γ and IL-2, and proportion of CD4
Indexed as
Identifiers
40067376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.